Novo Nordisk stock falls after raised forecast fails to change the debate over its obesity business
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
This is a summary aggregated from CNBC. Read the complete article on the original site:
Read full article at CNBC
